Dutch Patent Act 2026, What Chemical & Biotech Innovators in the Netherlands Must Do Now

The Dutch Patent Act 2026 is the most significant overhaul of the patent act Netherlands framework in three decades, and its impact is already reshaping filing, prosecution and enforcement decisions for chemical and industrial biotech innovators across the country. Whether you run a catalysis start-up in Eindhoven or lead IP strategy at a university spin-out developing novel enzyme platforms, the new Rijksoctrooiwet (NROW) introduces examined-patent procedures, tightened disclosure rules for biological materials, revised compulsory-licensing provisions and direct interplay with the Unified Patent Court, all of which demand immediate action. Delays in adapting your portfolio strategy risk weaker claim positions, missed transitional deadlines, and exposure to revocation challenges that did not exist under the prior regime.

TL;DR, three things to do right now:

• Audit every pending Dutch national filing. Determine whether it falls under transitional rules or must be refiled to benefit from the examined-patent track.
• Decide on UPC opt-out status for each European patent in your portfolio. Chemical and biotech patents with broad territorial value need a jurisdiction-by-jurisdiction risk assessment before the opt-out window closes.
• Review employee-invention clauses and material-transfer agreements (MTAs). The 2026 changes affect ownership allocation and deposit obligations, particularly for biological materials.

What the Dutch Patent Act 2026 Changes, Key Legislative Highlights

The new Dutch Patent Act replaces the Rijksoctrooiwet 1995 with a modernised framework that brings the Netherlands closer to the substantive examination standards familiar from the European Patent Office (EPO), while preserving the option for unexamined registrations in specific circumstances. Understanding the full dutch patent act impact requires clarity on four pillars of change.

First, the Act introduces a substantive examination track for national Dutch patents. Under the prior regime, Dutch patents were granted as registration patents without a novelty or inventive-step examination by the Netherlands Patent Office (Octrooicentrum Nederland). The NROW now allows applicants to request, and in certain categories mandates, a full examination covering novelty, inventive step and industrial applicability, aligning the national route more closely with EPC standards. The Netherlands Enterprise Agency (RVO) has published updated fee schedules and procedural timelines reflecting this change.

Second, the Act updates patentability exclusions and disclosure obligations for biotechnology. New provisions clarify the treatment of biological material that is not accessible to the public and cannot be described in the application in such a manner as to enable a person skilled in the art to reproduce the invention. Deposit requirements at a recognised international depositary authority, consistent with the Budapest Treaty, are now explicitly codified in the national statute, whereas previously they were inferred from EPO practice alone.

Third, the Act revises compulsory-licensing provisions. The grounds for compulsory licences have been expanded to align with EU-level harmonisation, and the procedures have been streamlined to reduce administrative delays.

Fourth, transitional provisions govern how pending applications, granted patents and ongoing oppositions migrate to the new regime, with specific lookback periods and conversion windows.

Quick Statutory Checklist

• Examined patents: New substantive examination route now available for national filings.
• Biotech disclosure: Explicit deposit rules for biological material codified in the Act.
• Compulsory licensing: Expanded grounds and streamlined procedures.
• Territorial scope: Updated provisions on the geographic reach of Dutch national patents, including Curaçao, Sint Maarten and Aruba clauses.
• UPC alignment: Statutory language drafted to facilitate coexistence with the Unified Patent Court system.
• Employee inventions: Clarified ownership-allocation rules for inventions created in an employment relationship.

Transitional Provisions & Timeline, What to Do Now

The transitional provisions of the Dutch Patent Act are the single most time-sensitive element for patent prosecution Netherlands teams to address. Pending applications, granted patents and ongoing proceedings each follow distinct migration paths, and missing a conversion window could leave innovators locked into the unexamined regime or exposed to validity challenges under new standards.

Which Pending Applications Are Affected?

Applications filed before the entry into force of the NROW remain subject to the procedural rules in effect at the time of filing, unless the applicant elects to convert them to the examined track within the statutory window. Industry observers expect that applicants with strong novelty positions, particularly chemical process patents and biotech platform patents, will benefit from voluntary conversion, as an examined patent carries significantly greater presumption of validity in litigation.

Applications filed after the Act’s commencement date are automatically subject to the new rules. For chemical and biotech innovators planning divisional filings or continuations, this means the parent application’s filing date determines which regime applies, while the divisional itself may fall under the new framework depending on when it is filed.

Deadlines for Opting into UPC or Staying National

The Dutch Patent Act 2026 does not alter the UPC Agreement directly, but its alignment provisions affect the practical calculus for Dutch patentees deciding whether to opt out of UPC jurisdiction. Under the UPC Agreement, holders of European patents (including those validated in the Netherlands) may file an opt-out application to keep their patents within the exclusive jurisdiction of national courts. The opt-out window remains available during the UPC’s transitional period. Patent holders who have not yet opted out should evaluate their entire portfolio now, as the interplay between the new national examination track and the UPC’s central revocation powers creates a new strategic dynamic, particularly for high-value biologics and specialty-chemical portfolios.

Patentability & Prosecution Implications for Chemical and Biotech Inventions

For R&D leaders and IP managers, the most consequential element of the dutch patent act impact is how patentability standards and prosecution workflows change for the specific claim types that dominate chemical and biotech portfolios, process claims, product-by-process claims, use claims, selection inventions, sequence-defined biologics and biological-material-dependent inventions. The introduction of substantive examination at the national level means that claim drafting must now satisfy scrutiny comparable to EPO prosecution, even for applications filed only at the Dutch national office.

Novelty and inventive-step assessments under the NROW follow the same substantive criteria as the European Patent Convention (EPC), but the procedural context is different. Dutch examiners will assess applications in accordance with guidelines that the Netherlands Patent Office is expected to publish in alignment with the EPO Guidelines for Examination. For chemical innovators, this means that selection inventions, where a specific compound or narrow range is claimed from a broader prior-art disclosure, must be supported by comparative data demonstrating an unexpected technical effect. Merely carving out a sub-range without supporting evidence is unlikely to survive examination.

The impact on biotech patents is equally substantial. The codification of deposit requirements for biological material that cannot be sufficiently described in the specification means that applicants must plan deposits at a recognised international depositary authority (IDA) under the Budapest Treaty before the filing date. Failure to deposit, or failure to include the prescribed deposit statement in the application as filed, risks irreversible loss of rights, a deposit cannot be cured retroactively.

Biotech-Specific Drafting Checklist

• Sequence listings: File WIPO Standard ST.26 XML sequence listings with every application that claims or references a nucleotide or amino-acid sequence. Ensure consistency between the sequence listing, the description and the claims.
• Deposit strategy: For inventions involving novel microbial strains, cell lines or other biological material that is not publicly available, complete the deposit at a recognised IDA (e.g., CBS-KNAW, DSMZ, ATCC) and include the deposit receipt number and depositary name in the application as filed.
• Enablement & sufficiency: Provide worked examples covering the full scope of the claims. For platform technologies, include at least one example per representative embodiment.
• Functional language: Limit functional claim language to features that are objectively verifiable. Where a functional definition is unavoidable, anchor it with structural or parametric alternatives in dependent claims.

Chemical Patent Strategy Netherlands, Drafting Checklist

• Process vs. product claims: Draft both product and process claims where possible. Under the NROW, process claims carry the same reversal-of-burden-of-proof provisions as under the EPC, which is critical for enforcement against suspected infringers manufacturing in-house.
• Use claims: Second-medical-use format (Swiss-type or EPC 2000 purpose-limited product claims) should be used where applicable. Ensure the dosage regimen or patient-population limitation is clearly defined.
• Selection inventions: Prepare tiered claim sets, broad genus, intermediate sub-genus and narrow selection, each supported by distinct experimental data showing a technical effect at that level of specificity.
• Markush structures: Review Markush claims for clarity and ensure that the defined group of alternatives shares a common structural feature relevant to the invention.

Opposition, Revocation and Enforcement, Dutch Courts, UPC and Dutch Patent Litigation 2026

The enforcement landscape for patent holders in the Netherlands has been transformed by two simultaneous developments: the new Dutch Patent Act and the continued expansion of the Unified Patent Court’s jurisdiction. Together, these changes recalibrate every enforcement decision for chemical and biotech patentees, from where to litigate, to how to structure evidence, to whether an opt-out serves long-term commercial interests.

Under the NROW, opposition and revocation procedures at the national level are modernised. The grounds for revocation now expressly track those available under the EPC, providing greater certainty for patent holders and challengers alike. Compulsory-licensing provisions have been expanded, and industry observers expect that competitors may increasingly invoke these provisions for essential chemical processes and biotech platform technologies, particularly where public-health or environmental-policy arguments can be raised.

The likely practical effect of examined patents is a stronger validity presumption in court, which benefits patentees in infringement proceedings but also means that revocation actions will require more rigorous prior-art searches and expert evidence. For chemical process patents, this elevates the importance of pre-litigation freedom-to-operate analysis and early evidence preservation, including retaining process samples and production records that may be needed to rebut infringement allegations or support a prior-use defence.

Unified Patent Court Netherlands, Jurisdictional Considerations and Opt-Out Strategy

The UPC’s local division in The Hague has jurisdiction over European patents validated in the Netherlands, unless the patent holder has opted out. The decision to opt out (or to withdraw a prior opt-out) should be made on a patent-by-patent basis, weighing factors including the geographic footprint of potential infringers, the desirability of cross-border injunctive relief, and the risk of central revocation. For high-value biotech patents covering biological materials with a single validated claim scope across multiple EU member states, the UPC offers the advantage of a single enforcement action, but also the risk that a single adverse validity decision eliminates protection across all participating states simultaneously.

Early indications suggest that chemical-sector patentees with strong portfolios concentrated in a small number of jurisdictions may prefer to retain national jurisdiction through an opt-out, while biotech companies with broad European commercial operations may benefit from UPC access for efficient pan-European enforcement.

Evidence and Infringement Proof for Process and Biotech Inventions

Dutch courts have well-established procedures for evidence preservation (including the bewijsbeslag, evidence seizure, mechanism), and the NROW preserves these tools. For process inventions in the chemical sector, the reversal of the burden of proof, where the defendant must demonstrate that its product was not made by the patented process, remains a powerful enforcement tool. Biotech patentees should ensure that they can demonstrate infringement through product testing, genetic sequencing or fingerprinting analysis, and should engage technical experts early in the litigation planning process.

Licensing, Freedom-to-Operate and Compliance for Regulated Biotech and Chemical Products

The dutch patent act impact extends beyond prosecution and enforcement to reshape how innovators manage intellectual property protection across borders. Freedom-to-operate (FTO) analysis under the new regime must account for the stronger validity presumption of examined patents, the broader compulsory-licensing grounds, and the UPC’s potential to consolidate revocation proceedings across borders.

For regulated biotech products, including biopharmaceuticals, food-tech enzymes and agricultural biologicals, patent-landscape mapping should be updated to reflect new filings under the examined track, which carry different enforcement weight than the registration patents that previously dominated the Dutch national system. Upstream and downstream licensing agreements should be reviewed to ensure that royalty triggers, sublicensing rights and termination clauses align with the new procedural realities.

When to Consider Defensive Publications and When to Patent

Under the new Act, the strategic calculation between patenting and defensive publication shifts. Because examined patents now carry genuine validity weight, securing patent protection for core innovations is more valuable than before. However, for incremental improvements or non-core processes, a well-timed defensive publication (e.g., through an industrial disclosure service or a peer-reviewed journal) can prevent competitors from obtaining patents while avoiding the cost of prosecution. SMEs and universities should adopt a tiered approach: patent the core platform, defensively publish the peripheral applications, and use trade-secret protection for manufacturing know-how that cannot be reverse-engineered.

IP Operations Checklist, Immediate Steps for R&D, Legal and Commercial Teams

The following ten-point checklist translates the 2026 changes into concrete tasks for cross-functional teams. Each action item identifies the responsible team and a recommended timeline.

1. Portfolio audit (IP team, within 30 days): Review every pending Dutch national filing and granted patent. Identify candidates for conversion to the examined track and flag patents requiring UPC opt-out reassessment.
2. Employee-invention review (Legal/HR, within 30 days): Confirm that employment contracts and invention-assignment clauses comply with the NROW’s clarified ownership rules.
3. MTA and collaboration-agreement update (Legal, within 60 days): Revise material-transfer agreements and joint-development contracts to reflect new deposit obligations and disclosure standards.
4. Prosecution-strategy revision (IP team, within 60 days): Update internal prosecution guidelines to account for substantive examination, tiered claim drafting and deposit requirements.
5. UPC opt-out decision matrix (IP/Commercial, within 60 days): For each European patent validated in the Netherlands, complete a structured opt-out analysis.
6. FTO landscape refresh (IP team, within 90 days): Re-run FTO searches for all active R&D programmes to identify newly examined Dutch patents that may affect commercial freedom.
7. Budget reallocation (Finance/IP, within 90 days): Examination fees, deposit costs and potential UPC litigation reserves must be factored into the annual IP budget.
8. Deposit compliance check (R&D/IP, within 90 days): Verify that all biological-material deposits are current, accessible and referenced correctly in pending and granted patents.
9. Training session (IP/R&D, within 120 days): Conduct internal workshops for researchers and engineers on the new filing requirements, invention-disclosure procedures and deposit protocols.
10. Monitoring protocol (IP team, ongoing): Establish a monitoring system for third-party filings under the examined track and UPC case law developments relevant to the chemical and biotech sectors.

Sample internal memo subject line: “Action required: Dutch Patent Act 2026, portfolio review and compliance steps. Deadline: [insert 30-day target date].”

Practical Scenarios, Case Studies and Recommended Playbooks

Scenario 1: Chemical process SME. A mid-sized chemical company in Rotterdam holds three Dutch national registration patents on a novel catalytic process. Under the NROW, the company should elect to convert at least its most commercially valuable patent to the examined track within the statutory window, strengthen its claim set with comparative data supporting the selection-invention argument, and retain the UPC opt-out for its European patent equivalent to maintain national-court jurisdiction where its primary competitor operates only in the Netherlands and Germany.

Scenario 2: University spin-out biotech. A Wageningen-based spin-out developing a proprietary microbial strain for sustainable food production has one pending Dutch national application and one PCT application entering the national phase. The team should prioritise completing the Budapest Treaty deposit for its strain, include the deposit reference in all national-phase applications, file under the examined track for maximum validity presumption, and evaluate UPC access for future pan-European enforcement once the product reaches commercial markets. The international IP country guide provides further context on coordinating multi-jurisdictional filings.

Conclusion, The Dutch Patent Act Impact Demands Action Now

The Dutch Patent Act 2026 is not a cosmetic update. It fundamentally changes how chemical and biotech innovators in the Netherlands secure, prosecute and enforce patent rights. The dutch patent act impact touches every stage of the innovation lifecycle, from first filing through to litigation and licensing.

Five priority actions with deadlines:

1. Complete a portfolio audit within 30 days of the Act’s entry into force.
2. File examined-track conversion requests within the six-month statutory window.
3. Finalise UPC opt-out decisions before the current transitional window closes.
4. Update all biological-material deposits and verify compliance within 90 days.
5. Revise employee-invention clauses and MTAs within 60 days.

Innovators who act decisively will emerge with stronger, more enforceable portfolios. Those who delay risk validity challenges, missed deadlines and competitive disadvantage. To discuss your specific portfolio, find an IP lawyer through the Global Law Experts directory.

Sources

1. Netherlands Enterprise Agency (RVO), Patents: System and Fees
2. WIPO, WIPOLex: Netherlands Patent Act
3. EPC, Commentary on the New Netherlands Patent Act (NROW)
4. IVIR, Unofficial Translation of the Rijksoctrooiwet 1995
5. Unified Patent Court, Official Information